サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：うっ血性心不全治療薬の世界市場：タイプ別、薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
市場調査レポート
商品コード
1351452

うっ血性心不全治療薬の世界市場：タイプ別、薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測

Congestive Heart Failure Drugs Market, By Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日
ページ情報
英文 297 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
うっ血性心不全治療薬の世界市場：タイプ別、薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2023年～2030年予測
出版日: 2023年09月01日
発行: AnalystView Market Insights
ページ情報: 英文 297 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のうっ血性心不全治療薬の市場規模は、2022年は66億90万米ドルとなり、2023年から2030年にかけてCAGR 15.8%で拡大すると予想されています。

うっ血性心不全治療薬市場 - 市場力学

  • 高齢者人口の増加、高血圧、肥満、糖尿病の罹患率の増加が業界の成長を増大させると予想されます。
  • 高齢者は併存疾患が多く、多くの薬剤を頻繁に服用するため、薬物相互作用や心不全を悪化させる状態に陥りやすいです。肥満は睡眠時無呼吸症候群や糖尿病など他の健康問題にも関連しており、いずれも心不全のリスクを高める。世界保健機関（WHO）によると、2020年には5歳未満の子どものうち3,900万人が過体重または肥満になる。新興経済諸国のヘルスケア・インフラが発展するにつれて、近代的な医療、特にCHFのような病気に対する薬物療法の必要性が高まり、市場に成長機会をもたらしています。しかし、心臓再同期療法（CRT）やその他の医療機器などの先進的な治療法は、時として医薬品の必要性を減らすことができます。

うっ血性心不全治療薬市場 - セグメンテーション分析

  • 世界のうっ血性心不全治療薬市場は、タイプ、薬剤クラス別、流通チャネル別、地域別に区分されます。
  • 市場はタイプによって左心不全、右心不全、高出力心不全の3つのカテゴリーに分けられます。左側心不全はより一般的であり、さらに駆出率低下型心不全（HFrEF）と駆出率維持型心不全（HFpEF）に細分化されます。
  • 市場は薬剤クラス別にACE阻害薬、アンジオテンシン2受容体拮抗薬、β遮断薬、利尿薬、アルドステロン拮抗薬、強心薬、その他の2つに分類される。アンジオテンシン2受容体拮抗薬が市場を独占しており、予測期間中もその優位性を維持するとみられます。アンジオテンシン2受容体拮抗薬（ARB）は、うっ血性心不全（CHF）を含む様々な心血管障害の治療に使用される必須薬剤クラス別であり、特にACE阻害薬に耐えられない患者に使用されます。
  • 市場は流通チャネルによって病院薬局、小売薬局、オンライン薬局の2つのカテゴリーに分けられる。市場を独占しているのは病院薬局部門です。病院薬局は、うっ血性心不全（CHF）を含む様々な疾患の治療薬の流通と調剤に不可欠です。

うっ血性心不全治療薬市場 - 地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。北米は、医療費の急増、心臓の健康に対する高い意識、ヘルスケアサービスの増加により、うっ血性心不全治療薬市場の成長を牽引すると予想されます。米国は一人当たりの医療費が世界最大級です。この多額の支出は、必然的に薬や治療法へのアクセスを増加させる。メディケア・メディケイド・サービスセンターによると、米国の医療費は2021年には2.7％成長し、4兆3,000億米ドル、1人当たり1万2,914米ドルに達します。国内総生産に占める医療費の割合は18.3％です。欧州は、研究開発への支出の増加により、この市場の成長において2番目に大きな地域を占めています。

うっ血性心不全治療薬市場 - 競合情勢

うっ血性心不全（CHF）治療薬市場には、既存の巨大製薬企業から最先端治療に注力する新規参入企業まで、さまざまな企業が参入しています。著名な製薬会社数社がCHFの新規治療薬を開発している一方で、特に初期のCHF治療薬の多くが特許切れを迎えているため、ジェネリック医薬品市場も大きく成長しています。CHF治療薬市場では、十分な数の合併・買収が行われており、大手製薬会社は新規治療薬をパイプラインに加えるため、中小企業の買収や提携を行っています。例えば、米国とカナダ以外ではMSDとして知られるメルク社は、2023年3月6日、米国食品医薬品局（FDA）が、症候性慢性心不全で駆出率が45％未満の成人において、心不全による入院または外来での静脈内利尿の必要性に伴う心血管死と心不全による入院のリスクを低減する可溶性グアニル酸シクラーゼ（sGC）刺激薬VERQUVOを承認したと発表しました。

目次

第1章 うっ血性心不全治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 うっ血性心不全治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 うっ血性心不全治療薬業界の研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 うっ血性心不全治療薬市場：COVID-19の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 うっ血性心不全治療薬市場情勢

  • うっ血性心不全治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 うっ血性心不全治療薬市場 - タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • 左心不全
    • 右心不全
    • 高心拍出性心不全

第8章 うっ血性心不全治療薬市場 - 薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • ACE阻害剤
    • アンジオテンシン2受容体遮断薬
    • ベータブロッカー
    • 利尿薬
    • アルドステロン拮抗薬
    • 変力薬
    • その他

第9章 うっ血性心不全治療薬市場 - 流通チャネル別

  • 概要
    • 流通チャネル別のセグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第10章 うっ血性心不全治療薬市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析 - うっ血性心不全薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Bayer AG
    • Novartis AG
    • Merck &Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson &Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Novo Nordisk A/S

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Congestive Heart Failure Drugs Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Congestive Heart Failure Drugs Market, by Type 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Congestive Heart Failure Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Congestive Heart Failure Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Congestive Heart Failure Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
目次
Product Code: ANV1694

REPORT HIGHLIGHT

Congestive heart failure drugs Market size was valued at USD 6,600.9 Million in 2022, expanding at a CAGR of 15.8% from 2023 to 2030.

Congestive heart failure (CHF) is a complex clinical illness caused by any anatomical or functional cardiac problem that inhibits the heart's ability to fill with or pump enough blood throughout the body. The most effective therapy for CHF is generally determined by the underlying cause of the heart failure, its severity, and any other medical disorders the patient may have. The goal of treatment for chronic congestive heart failure (CHF) is to enhance symptom management and quality of life, reduce hospitalizations, and lower overall mortality.

Congestive heart failure drugs Market - Market Dynamics:

  • A rise in the geriatric population and an increase in the incidence of hypertension, obesity, and diabetes are expected to augment industry growth.
  • Elderly people have more comorbid diseases and frequently take many drugs, making them more vulnerable to drug interactions and conditions that exacerbate heart failure. Obesity is also linked to other health issues such as sleep apnea and diabetes, both of which raise the risk of heart failure. According to the World Health Organization, 39 million children under the age of 5 were overweight or obese in 2020. As rising economies' healthcare infrastructure develops, there is an increasing need for modern medical treatments, especially medications for illnesses such as CHF providing growth opportunities for the market. However, Advanced treatments such as cardiac resynchronization therapy (CRT) and other medical devices can occasionally reduce the need for pharmaceuticals.

Congestive heart failure drugs Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Congestive heart failure drugs market is estimated to grow annually at a CAGR of around 15.8% over the forecast period (2023-2030)
  • The Congestive heart failure drugs industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on type segmentation, Left-sided Heart Failure was predicted to show maximum market share in the year 2022
  • Based on drug class segmentation, Angiotensin II Receptor Blockers (ARBs were the leading type in 2022
  • Based on distribution channel segmentation, hospital Pharmacies were the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Congestive Heart Failure Drugs Market- Segmentation Analysis:

  • The Global Congestive Heart Failure Drugs Market is segmented on the basis of Type, Drug Class, Distribution Channel, and Region.
  • The market is divided into three categories based on type: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure. Left-sided heart failure is more prevalent, and it is further subdivided into heart failures with reduced ejection fraction (HFrEF) and heart failures with maintained ejection fraction (HFpEF).
  • The market is divided into two categories based on Drug Class: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others. The Angiotensin 2 Receptor Blockers dominate the market and are likely to maintain their dominance during the forecast period. Angiotensin II Receptor Blockers (ARBs) are an essential class of drugs used to treat a variety of cardiovascular disorders, including congestive heart failure (CHF), particularly in patients who cannot tolerate ACE inhibitors.
  • The market is divided into two categories based on Distribution Channels: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies sector dominates the market. Hospital pharmacies are essential in the distribution and dispensing of medications for a variety of diseases, including congestive heart failure (CHF).

Congestive heart failure drugs Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to drive the growth of the Congestive Heart Failure Drugs Market, due to a Surge in medical spending, high awareness about cardiac health, and an increase in the availability of healthcare services. The United States has one of the world's largest per capita healthcare expenses. This significant expenditure inevitably increases access to medications and therapies. According to the Center for Medicare and Medicaid Service, U.S. healthcare spending will grow 2.7 percent in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3 percent. Europe held the second largest region for the growth of this market, due to a rise in spending on research & development activities.

Congestive heart failure drugs Market- Competitive Landscape:

The market for congestive heart failure (CHF) medications has seen a variety of participants, ranging from established pharmaceutical behemoths to newer entrants focused on cutting-edge therapy. While several prominent pharmaceutical companies are developing novel treatments for CHF, there is also a substantial market for generic medications, especially because many of the earlier CHF treatments have had their patents expire. The CHF medicine market has seen a sufficient number of mergers and acquisitions, with larger players acquiring or collaborating with smaller companies to bring novel treatments into their pipelines. For Example, on 6 march 2023, Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

Recent Developments:

On March 1, 2023, Amgen (NASDAQ: AMGN) announced new Repatha (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, a siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET KEY PLAYERS

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY TYPE

  • Left-sided Heart Failure
  • Right-sided Heart Failure
  • High-output Heart Failure

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DRUG CLASS

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Congestive Heart Failure Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Congestive Heart Failure Drugs Market Snippet by Type
    • 2.1.2. Congestive Heart Failure Drugs Market Snippet by Drug Class
    • 2.1.3. Congestive Heart Failure Drugs Market Snippet by Distribution Channel
    • 2.1.4. Congestive Heart Failure Drugs Market Snippet by Country
    • 2.1.5. Congestive Heart Failure Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Congestive Heart Failure Drugs Key Market Trends

  • 3.1. Congestive Heart Failure Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Congestive Heart Failure Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Congestive Heart Failure Drugs Market Opportunities
  • 3.4. Congestive Heart Failure Drugs Market Future Trends

4. Congestive Heart Failure Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Congestive Heart Failure Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Congestive Heart Failure Drugs Market Landscape

  • 6.1. Congestive Heart Failure Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Congestive Heart Failure Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Left-sided Heart Failure
    • 7.1.3. Right-sided Heart Failure
    • 7.1.4. High-output Heart Failure

8. Congestive Heart Failure Drugs Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 8.1.2. ACE Inhibitors
    • 8.1.3. Angiotensin 2 Receptor Blockers
    • 8.1.4. Beta Blockers
    • 8.1.5. Diuretics
    • 8.1.6. Aldosterone Antagonists
    • 8.1.7. Inotropes
    • 8.1.8. Others

9. Congestive Heart Failure Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Congestive Heart Failure Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Congestive Heart Failure Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Congestive Heart Failure Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Congestive Heart Failure Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Congestive Heart Failure Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Congestive Heart Failure Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Congestive Heart Failure Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bayer AG
    • 11.2.2. Novartis AG
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. AstraZeneca
    • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.6. Amgen Inc.
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. Pfizer, Inc.
    • 11.2.9. Johnson & Johnson Services, Inc.
    • 11.2.10. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Novo Nordisk A/S

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us